Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 1:25 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 1,012 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adverse Events Clear all
Active, not recruiting Phase 3 Interventional

A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

NCT06063967
View directory record Official record
Conditions
Crohn's Disease
Interventions
Risankizumab SC, Placebo for risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
79
States / cities
Sun City, Arizona • Corona, California • Coronado, California + 65 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Nov 1, 2026, 1:25 PM EST
Completed No phase listed Observational

Testing a Spanish Version of a Patient Toxicity Questionnaire

NCT01517152
View directory record Official record
Conditions
Breast Cancer, Colon Cancer, Lung Cancer, Lymphoma, Myeloma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Nov 1, 2026, 1:25 PM EST
Active, not recruiting Phase 1 Interventional

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

NCT05618028
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
Interventions
ABBV-525
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
13
States / cities
Los Angeles, California • New Haven, Connecticut • Miami Beach, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Nov 1, 2026, 1:25 PM EST
Completed Phase 2 Interventional

Effects of Uridine Supplementation on Metabolic Side Effects of Stavudine and Zidovudine

NCT00471614
View directory record Official record
Conditions
HIV Infections, Insulin Resistance, Hyperlactatemia
Interventions
NucleomaxX (contains uridine)
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Nov 1, 2026, 1:25 PM EST
Completed Phase 1 Interventional

Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization

NCT02118987
View directory record Official record
Conditions
Drug Allergy
Interventions
Omalizumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Nov 1, 2026, 1:25 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Identifying Which Adverse Events Associated With Dry Needling Should be Included For Informed Consent: A Modified e-Delphi Study

NCT05300815
View directory record Official record
Conditions
Dry Needling
Interventions
Delphi Questionaire
Other
Lead sponsor
Youngstown State University
Other
Eligibility
18 Years to 100 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Nov 1, 2026, 1:25 PM EST
Completed No phase listed Observational

A Prospective Study of a New Non-Invasive Cardiac Output Monitor in Children Undergoing General Anesthesia

NCT01499615
View directory record Official record
Conditions
Children Receiving General Anesthesia
Interventions
cardiac monitor
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
1 Hour to 18 Years
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Nov 1, 2026, 1:25 PM EST
Completed No phase listed Observational

PARA-HEART Pilot Implementation

NCT02709135
View directory record Official record
Conditions
Acute Coronary Syndrome, Chest Pain
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Nov 1, 2026, 1:25 PM EST
Completed Not applicable Interventional

Randomized, Double-Blind Cross-Over Trial Of Buprenorphine and Low-Dose Naloxone Versus Buprenorphine

NCT00679458
View directory record Official record
Conditions
Pain
Interventions
buprenorphine and low-dose naloxone, buprenorphine alone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2010 · Synced Nov 1, 2026, 1:25 PM EST
Active, not recruiting No phase listed Observational

Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity

NCT05036252
View directory record Official record
Conditions
Breast Cancer, HER2-positive Breast Cancer, HER2-positive Metastatic Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage IV, Cardiotoxicity
Interventions
Cardiopulmonary Exercise Test, Echocardiogram, Echocardiography
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 1, 2026, 1:25 PM EST
Recruiting Phase 2 Interventional

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

NCT07024784
View directory record Official record
Conditions
Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC)
Interventions
IMGN151, Carboplatin, Bevacizumab, Olaparib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Los Angeles, California • Aurora, Colorado • Minneapolis, Minnesota + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 1, 2026, 1:25 PM EST
Recruiting Phase 2 Interventional

Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin

NCT05730283
View directory record Official record
Conditions
Ototoxicity, Drug-Induced
Interventions
ORC-13661, Placebo
Drug
Lead sponsor
Kevin Winthrop
Other
Eligibility
18 Years to 80 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
San Francisco, California • Denver, Colorado • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 1, 2026, 1:25 PM EST
Not yet recruiting Phase 1 Interventional

Psilocybin After Trauma Surgery for Pain

NCT07406828
View directory record Official record
Conditions
Pain Management, Postoperative Pain
Interventions
Psilocybin (Usona Institute), Postoperative analgesia
Drug
Lead sponsor
Trent Emerick
Other
Eligibility
25 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Nov 1, 2026, 1:25 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

How Clinical and Personal Information Shape Physicians' Risk Judgments

NCT07162376
View directory record Official record
Conditions
Major Adverse Cardiac Event (MACE)
Interventions
Personal Information Disclosure
Behavioral
Lead sponsor
University of Maryland, College Park
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Nov 1, 2026, 1:25 PM EST
Active, not recruiting No phase listed Observational

Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer

NCT05078190
View directory record Official record
Conditions
Breast Cancer, Cardiotoxicity, Drug-Related Side Effects and Adverse Reactions, Cardiovascular Diseases
Interventions
Social Determinants of Health
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2039
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Nov 1, 2026, 1:25 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess Adverse Events and How Oral Emraclidine Moves Through the Body of Adult Healthy Volunteers

NCT07587008
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Emraclidine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Nov 1, 2026, 1:25 PM EST
Recruiting Phase 2 Interventional

Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair

NCT07226791
View directory record Official record
Conditions
Ventral Hernia
Interventions
AGN-151607-DP, Placebo for AGN-151607-DP
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
13
States / cities
Riverside, California • Jacksonville, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Nov 1, 2026, 1:25 PM EST
Enrolling by invitation Phase 3 Interventional

Evaluating Cognitive Changes on Patients in Chemotherapy (ECCPC)

NCT06950190
View directory record Official record
Conditions
Chemotherapy-related Cognitive Impairment
Interventions
Low-Intensity Walking Intervention, Control Group Intervention
Behavioral
Lead sponsor
Ellis Medicine
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Schenectady, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Nov 1, 2026, 1:25 PM EST
Recruiting Phase 2 Interventional

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

NCT06846320
View directory record Official record
Conditions
Generalized Anxiety Disorder (GAD)
Interventions
ABBV-932, Placebo for ABBV-932, Antidepressant Therapy (ADT)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
49
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Nov 1, 2026, 1:25 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers

PARIS or PAtch RIng Study: A Trial to Evaluate NuvaRing Versus OrthoEvra

NCT00269620
View directory record Official record
Conditions
Contraception
Interventions
ethinyl estradiol/etonogestrel vaginal ring, ethinyl estradiol/norelgestromin transdermal contraceptive
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
Female only
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
10
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2008 · Synced Nov 1, 2026, 1:25 PM EST
Completed Phase 4 Interventional Results available

Ketamine as an Augmentation Strategy for Electroconvulsive Therapy (ECT) in Depression

NCT01881763
View directory record Official record
Conditions
Unipolar Depression, Bipolar Depression
Interventions
Ketamine, Methohexital
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Nov 1, 2026, 1:25 PM EST
Terminated No phase listed Observational

Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib

NCT04827563
View directory record Official record
Conditions
Multiple Myeloma, Shortness of Breath, Dyspnea, Cardiotoxicity
Interventions
EndoPAT, Blood Pressure Cuff, Echocardiogram, Quality of Life Assessment, Blood Tests
Device · Diagnostic Test · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Nov 1, 2026, 1:25 PM EST
Recruiting Phase 1Phase 2 Interventional

Evaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepository

NCT06789601
View directory record Official record
Conditions
Malignancy, Immune Related Adverse Events
Interventions
Informatics system for eligibility monitoring, Standard eligibility monitoring
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Nov 1, 2026, 1:25 PM EST
Completed No phase listed Observational

Assessment of Immediate Adverse Reactions From Dotarem in Children Under 2 Years of Age

NCT02609919
View directory record Official record
Conditions
Adverse Reaction to Drug, Allergic Reaction to Contrast Media
Interventions
Gadoteric Acid
Drug
Lead sponsor
St. Louis University
Other
Eligibility
Up to 2 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 13, 2019 · Synced Nov 1, 2026, 1:25 PM EST